New drug trial aims to slow muscle loss in rare genetic disease
NCT ID NCT06411912
Summary
This study tested an investigational drug called NIDO-361 in men with spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease. The goal was to see if the drug is safe and if it can help preserve muscle volume and improve physical function over one year. Fifty-four participants were randomly assigned to receive either the drug or a placebo, and neither they nor the doctors knew which they were getting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL AND BULBAR MUSCULAR ATROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedale Università di Padova
Padova, Italy
-
IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
-
Kyungpook National University Chilgok Hospital
Daegu, South Korea
-
Rigshospitalet, Klinik for Nerve- og Muskelsygdomme & Copenhagen Neuromuscular Center
Copenhagen, Denmark
-
University of College London Hospital (UCLH)
London, United Kingdom
Conditions
Explore the condition pages connected to this study.